
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences Inc is focused on developing innovative treatments for Duchenne muscular dystrophy (DMD) and has projected significant revenue growth with SGT-003, anticipated to reach risk-adjusted revenues of $1 billion by 2033, up from $90 million in 2028. Early clinical data suggest promising cardiac benefits from SGT-003, with an 8% increase in mean left ventricular ejection fraction observed in patients, indicating potential expansion into the total addressable DMD market. Additionally, improvements in critical biomarkers related to muscle integrity support the company's progress in its gene therapy initiatives, reinforcing a positive outlook for its future clinical developments.
Bears say
Solid Biosciences Inc faces a concerning outlook due to significant risks associated with its lead product, SGT-003, which is primarily aimed at treating Duchenne muscular dystrophy. The company's financial projections hinge on achieving regulatory approval for SGT-003; however, any failure or delays in this process could necessitate downward revisions of its risk-adjusted projections, adversely impacting share price. Additionally, challenges in developing adequate manufacturing capacity for SGT-003 could further constrain sales and revenue potential, compounding the company's vulnerabilities in a competitive and complex gene therapy market.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares